New breakthrough medicines for Hepatitis C present an important choice about setting goals and taking systemic action to achieve public health advances in the United States. Despite appearing to offer cure rates greater than 90 percent, high-priced Hepatitis...
Filed under: Public Health, Global Health, Disparities, Population Health, Featured, Costs and Spending, Equity and Disparities, Drugs and Medical Technology, Gilead, hepatitis C, Sovaldi